NCT05433142View on ClinicalTrials.gov

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

June 13, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

November 30, 2027

Conditions
Clear Cell Renal Cell Carcinoma
Interventions
BIOLOGICAL

XmAb819

Monoclonal Bispecific Antibody

Trial Locations (8)

10032

RECRUITING

Columbia University Medical Center, New York

10065

RECRUITING

Memorial Sloan Kettering, New York

27710

RECRUITING

Duke University, Durham

30322

RECRUITING

Winship Cancer Institute of Emory University, Atlanta

37203

RECRUITING

Sarah Cannon Research Institute, LLC, Nashville

60637

RECRUITING

The University of Chicago Medical Center, Chicago

91010

RECRUITING

Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

All Listed Sponsors
lead

Xencor, Inc.

INDUSTRY

NCT05433142 - Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter